ASMB Terminates Material Agreement, Signals Strategic Shift

TL;DR

**ASMB just terminated a key agreement, watch for details on what's next.**

AI Summary

Assembly Biosciences, Inc. (ASMB) filed an 8-K on January 17, 2024, reporting the termination of a material definitive agreement, effective January 11, 2024. This termination could signal a shift in the company's strategic partnerships or product development plans, which might impact future revenue streams or operational costs. Investors should monitor for further announcements regarding the reasons for termination and any new agreements, as this could affect the company's valuation and growth prospects.

Why It Matters

The termination of a material agreement can significantly alter a company's financial outlook, potentially impacting its revenue, expenses, and future product pipeline. Investors need to understand the implications for Assembly Biosciences' long-term strategy and profitability.

Risk Assessment

Risk Level: medium — The termination of a material agreement introduces uncertainty regarding future business operations and financial performance, posing a moderate risk to investors.

Analyst Insight

A smart investor would seek further information from Assembly Biosciences regarding the specific agreement terminated and the reasons behind it, as well as any potential impact on their product pipeline or financial projections, before making investment decisions.

Key Players & Entities

• Assembly Biosciences, Inc. (company) — the registrant filing the 8-K
• January 11, 2024 (date) — date of the earliest event reported (termination effective date)
• January 17, 2024 (date) — date the 8-K was filed
• ASMB (company) — trading symbol for Assembly Biosciences, Inc.
• The Nasdaq Global Select Market (company) — exchange where ASMB Common Stock is registered

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 ASMB The Nasdaq Global Select Marke
• $0.8 m — tones through development been met, was $0.8 million, a portion of which was earned an
• $0.1 m — id annual diligence maintenance fees of $0.1 million, with any milestone payments bein

Filing Documents

• asmb-20240111.htm (8-K) — 40KB
• 0000950170-24-005024.txt ( ) — 181KB
• asmb-20240111.xsd (EX-101.SCH) — 49KB
• asmb-20240111_htm.xml (XML) — 5KB

02 Termination of a Material Definitive Agreement

Item 1.02 Termination of a Material Definitive Agreement. On January 11, 2024, Assembly Biosciences, Inc. (the Company) notified the Indiana University Innovation and Commercialization Office that the Company has decided to terminate the Exclusive License Agreement dated September 3, 2023 by and between Indiana University Research and Technology Corporation (IURTC) and Assembly Pharmaceuticals, Inc., the Company's predecessor (the License Agreement), as amended by Amendment No. 1 to the License Agreement dated February 28, 2017 and Amendment No. 2 to the License Agreement dated July 10, 2020. The termination of the License Agreement will be effective on April 11, 2024, 90 days following the delivery of the termination notice. Pursuant to the License Agreement, the Company acquired, with rights to sublicense, the rights to develop and commercialize products associated with multiple patents and patent applications covering aspects of its hepatitis B virus (HBV) program held by IURTC, including its first generation capsid assembly modulator (CAM), vebicorvir (VBR). In July 2022, the Company discontinued further clinical development of VBR based on review of interim on-treatment efficacy from two triple combination studies, and focused its HBV program on the Company's next-generation CAMs, which were designed and developed to optimize activity against both CAM mechanisms of action. These next-generation CAMs were internally discovered and developed CAMs. As a part of the License Agreement, the Company would have been obligated to make milestone payments based upon the successful accomplishment of clinical and regulatory milestones. The aggregate amount of all performance milestone payments under the License Agreement, had all performance milestones through development been met, was $0.8 million, a portion of which was earned and paid. Under the License Agreement, the Company would have been obligated to pay IURTC royalties based on net sales of the licensed techno

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Assembly Biosciences, Inc. Date: January 17, 2024 By: /s/ John O. Gunderson John O. Gunderson VP, General Counsel and Corporate Secretary 2

View Full Filing

View this 8-K filing on SEC EDGAR